Regeneron Pharmaceuticals (REGN 0.39%) is a growing biotech company that generates a ton of free cash flow. Over the years, it has obtained approval or authorization for 12 medicines. Its strong in-house development has made it one of the larger healthcare stocks in the world, with a market capitalization in excess of $90 billion. In five years, shares of Regeneron have risen close to 130%, soundly outperforming the S&P 500 index and its more modest 87% gains. The business has been a popular investment opti ...

Regeneron Pharmaceuticals Inc. ASH 2023 Investor Conference Call Summary Company Overview - **Company**: Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) - **Event**: American Society of Hematology 2023 Investor Conference Call - **Date**: December 14, 2023 Key Points Industry Focus - Regeneron is focusing on becoming a leader in **oncology** and **hematology** with a robust pipeline of investigational medicines, particularly in **bispecific antibodies** and **monoclonal antibodies** [4][5][6] Clinical Pipeline and Innovations - The company has **10 programs** in clinical development within hematology, with one approved product [7][8] - Recent advancements include: - **Linvoseltamab** for multiple myeloma, showing a **71% objective response rate** and **46% complete response rate** in patients [15][16] - **Odronextamab** for lymphoma, with an **81% overall response rate** in follicular lymphoma and **52% in diffuse large B-cell lymphoma** [19][20] - A **C5 program** combining an antibody with siRNA, showing promising results in controlling hemolysis in PNH patients [26][27] Combination Therapies - A novel combination approach using **Dupixent** and **linvoseltamab** aims to potentially cure severe allergies by targeting IgE-producing plasma cells [10][11][12][58] - The combination is expected to eliminate IgE cells and prevent their reconstitution, addressing a significant unmet medical need in allergy treatment [13][58] Regulatory and Development Plans - **Linvoseltamab** is set for a **BLA filing** by the end of December 2023, with a **MAA submission** planned for the first half of 2024 [14][17] - **Odronextamab** has a **PDUFA date** of March 31, 2024, with ongoing studies in earlier lines of therapy [19][25] - The C5 program is advancing towards pivotal trials in **Geographic Atrophy** and other complement-mediated diseases [27][30] Safety and Efficacy - Linvoseltamab demonstrated a **manageable safety profile**, with **46%** experiencing mild cytokine release syndrome (CRS) [16][22] - Odronextamab showed a **generally manageable safety profile**, with no Grade 4 or 5 CRS events reported [22][23] Future Directions - Regeneron is exploring **Factor XI antibodies** for coagulation disorders, with plans for rapid advancement into registration trials starting in 2024 or early 2025 [31][32] - The company is also pursuing **CRISPR technology** for gene editing, with promising preclinical data for treating conditions like **Hemophilia B** [35][36] Market Positioning - Regeneron aims to establish a strong presence in the hematology-oncology market with its innovative therapies, particularly in light of the increasing prevalence of allergic diseases and hematological conditions [25][58] Conclusion - Regeneron is making significant strides in developing innovative therapies across oncology and hematology, with a focus on combination therapies and advanced clinical programs that address unmet medical needs [38][41]

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Piper Sandler 35th Annual Healthcare Conference Call November 28, 2023 8:30 AM ET Company Participants Bob Landry - Chief Financial Officer Ryan Crowe - Vice President, Investor Relations Conference Call Participants Chris Raymond - Piper Sandler Chris Raymond Okay. I think we are going to go ahead and started. Thanks, everybody, for being here. My name is Chris Raymond. I’m one of the biotech analysts here at Piper Sandler. Welcome the 35th Annual Piper Sandler ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Jefferies London Healthcare Conference November 15, 2023 9:30 AM ET Company Participants Bob Landry - CFO Ryan Crowe - IR Conference Call Participants Akash Tewari - Jefferies Akash Tewari Good afternoon, everyone. I was just joking with the Regeneron team. There is a biotech bear market. I don't see it in London. These are packed rooms. It’s really great to see everyone. And this is -- I also think that we are going to have an XPI rally, but that's my hot take ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Truist Securities BioPharma Symposium November 8, 2023 3:20 PM ET Company Participants Dr. Len Schleifer - President and Chief Executive Officer Ryan Crowe - Investor Relations Conference Call Participants Robyn Shelton - Truist Securities Robyn Shelton Good morning, everyone. What a delight to have Dr. Len Schleifer here today. I think I've known Len since I was a baby analyst. A really bad one, but much better now. And with them, we also have Ryan Crowe from I ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) UBS Biopharma Conference Call November 9, 2023 11:00 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations Brook Jennings - Vice President, Immunology Marketing Conference Call Participants Colin Bristow - UBS Colin Bristow Well, good morning, and welcome to the UBS Biopharma Conference. I am Colin Bristow, one of the biotech analysts here. It's my pleasure to have Regeneron Pharmaceuticals with us today. On behalf of the company, we have Bro ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Ryan Crowe – Vice President-Investor Relations Leonard Schleifer – President and Chief Executive Officer George Yancopoulos – President and Chief Scientific Officer Marion McCourt – Executive Vice President and Head-Commercial Bob Landry – Executive Vice President and Chief Financial Officer Conference Call Participants Evan Seigerman – BMO Capital Markets Mohit Bansal – Wells Farg ...

Re ge ne r on Cor por a t e Pr e s e nt a t ion N o v e m b e r 2 0 2 3 This non-promotional presentation contains investigational data as well as forward-looking statements; actual results may vary materially. Note regarding forward-looking statements and non-GAAP financial measures Thispresentationincludesforward-lookingstatementsthatinvolverisksanduncertaintiesrelatingtofutureeventsandthefutureperformanceofRegeneronPharmaceuticals,Inc.("Regeneron"orthe"Company"),andactualeventsorresults maydiffermaterial ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 000-19034 REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York ...

https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/s_m_content_28724af4cc20789ed78ef5567d89200d.html ...